文献速递肿瘤 PET/CT甲状腺核医学

肾上腺腺瘤中高18氟-DCFPyL摄取

High 18Fluor-DCFPyL Uptake in Adrenal Adenomas.
PubMed 文献 · Clin Nucl Med · 2017-01-01

一例77岁前列腺癌患者在黄体生成素释放激素激动剂治疗期间因前列腺特异性抗原进展接受18氟-DCFPyL PET/CT,显示双侧增大肾上腺摄取增高;平扫CT提示左侧肾上腺腺瘤,基于多期增强CT高阳性预测值(98%),右侧肾上腺腺瘤也可能存在。

要点

  • 18氟-DCFPyL PET/CT可显示双侧增大肾上腺的摄取增高。
  • 平扫CT提示左侧肾上腺腺瘤,右侧腺瘤也可能存在。
  • 多期增强CT阳性预测值为98%。

核心结论

  • 18氟-DCFPyL在双侧增大肾上腺中显示摄取,平扫CT提示左侧肾上腺腺瘤,右侧肾上腺腺瘤也可能存在。

研究设计与样本

  • 本文为病例报告,描述一例77岁前列腺癌患者在黄体生成素释放激素激动剂治疗期间因前列腺特异性抗原进展接受18氟-DCFPyL PET/CT检查。

主要发现

  • PET/CT显示双侧增大肾上腺18氟-DCFPyL摄取。
  • 非增强CT扫描提示左侧肾上腺腺瘤。
  • 多期对比增强CT的阳性预测值为98%,据此右侧肾上腺腺瘤也可能存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radioisotope-labeled prostate-specific membrane antigen (PSMA) tracers have been proven accurate for detection of prostate cancer localizations. Uptake of those tracers in other malignant and benign lesions has been reported, including faint accumulation of Ga-PSMA-HBED-CC in adrenal adenoma. A 77-year-old man with prostate carcinoma was scanned with F-DCFPyL, a promising F-labeled PSMA ligand, for prostate-specific antigen progression while on luteinizing hormone-releasing hormone agonist therapy. The PET/CT shows F-DCFPyL uptake in bilateral enlarged adrenals. Non-contrast-enhanced CT scan indicated left adrenal adenoma. Regarding the high positive predictive value of multiphase contrast-enhanced CT (98%), presence of right adrenal adenoma is also likely.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Peper JGK, Srbljin S, van der Zant FM, et al. High 18Fluor-DCFPyL Uptake in Adrenal Adenomas. Clin Nucl Med. 2017. PMID: 28825951. doi:10.1097/RLU.0000000000001808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。